ALPHA.PA - Pharnext SA
Pharnext SA
9 rue des Filles Saint-Thomas
Paris 75002
France
33 1 41 09 22 30
https://pharnext.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Daniel E. Cohen | Director | 319,3k | S.O. | 1953 |
| Mr. Hugo Brugiere M.Sc. | CEO & Chairman | S.O. | S.O. | S.O. |
| Mr. Ilya Chumakov Ph.D., D-Sc | Co-Founder, Chairman of Scientific Advisory Board and Director | S.O. | S.O. | S.O. |
| Mr. Xavier Paoli M.Sc. | Chief Operating Officer | S.O. | S.O. | S.O. |
| Mr. Antoine Gravelle | Gen. Counsel | S.O. | S.O. | S.O. |
| Ms. Susanne Dorn | Chief Regulatory Officer | S.O. | S.O. | S.O. |
| Mr. Rodolphe Hajj | Chief Pharmacology Officer | S.O. | S.O. | S.O. |
| Ms. Viviane Bertrand | Chief Preclinical Drug Devel. Officer | S.O. | S.O. | S.O. |
| Mr. Philippe Rinaudo | Chief Data Science Officer | S.O. | S.O. | S.O. |
| Mr. Abhijit Pangu | Head of Regulatory Affairs | S.O. | S.O. | S.O. |
Description
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Pharnext SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
